# Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

> **NCT05318469** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yuan Yuan** · enrollment: 34 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Ivermectin
- **DRUG:** Balstilmab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05318469
- **Lead sponsor:** Yuan Yuan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-13
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05318469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05318469, "Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05318469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*